Navigation Links
Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Date:10/25/2007

Cell Therapeutics, Inc. (CTI) announces data presented at AACR-NCI-EORTC

Symposium

SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a wholly-owned subsidiary of CTI, announced new preclinical data from several of its drug candidates during the 19th annual AACR-NCI-EORTC Symposium.

"These studies show potential progress toward identifying specific tumor types with a higher likelihood of demonstrating response to anti-cancer compounds early in clinical development and are critical to our goal of a highly focused clinical development strategy," said Jack W. Singer, M.D., Chief Medical Officer of CTI.

A new class of thienopyrimidine Src inhibitors demonstrates potent growth suppression of imatinib resistant Ba/F3 cells harboring a wide range of BCR-ABL mutations, including the CML relevant T315I (Abstract #B238)

Spyro Mousses, Ph.D., Senior Investigator and Director, Cancer Drug Development Laboratory at the Translational Genomics Research Institute (TGen) presented preclinical data that showed two thienopyrimidine Src inhibitors work in imantinib-resistant tumors, including the most frequent mutation leading to relapse. The study showed the Src inhibitors retained potent and non-selective cytotoxicity (at sub-micromolar concentrations) in cell lines previously shown to be susceptible and resistant to imatinib, including the T315I mutant cell line. The data suggest that the thienopyrimidine Src inhibitors may represent a new class of drugs with in vitro activity against chronic myelogenous leukemia (CML) variants with BCR-ABL mutations, warranting their exploration as potential new treatments for patients with imatinib-resistant forms of cancer. Preliminary in vitro data suggest these compounds are selective for Src.

"Continued development of these compounds is warranted to more extensively evaluate their selectivit
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), ... on cardiac and vascular surgery, announced today that it ... of Vice President, Research and Development; and David P. ... Market Development Surgical Adhesives and Starch Medical Relations.  Dr. ...
... LOUIS, Jan. 4, 2012 Express Scripts now provides ... HealthBridge Pharma & Biotech services. CuraScript, a wholly owned ... suite of services, will be among a limited number ... EYLEA (aflibercept) Injection was approved by the ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5Express Scripts HealthBridge Pharma & Biotech to Provide Specialty Pharmacy and Specialty Distribution Services for EYLEA™ (aflibercept) Injection 2
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... confirmed today that its Krames Patient Education content is ICD-10 ready and available ... ready for the new ICD-10 code sets, which are more targeted and return ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, the ... professional Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko competes ... training and recovery. , With a focus on technology and comfort, Zensah® has ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of Philosophy ... doctoral program at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s ... prepare advanced practice nurses for the highest level of clinical nursing practice. , ...
(Date:8/27/2015)... CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development ... to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Market ... market research promotion on the Internet. MarketPublishers.com is now authorised to distribute ... the partnership agreement, Natalie Aster, Assistant Manager at Partners Department, noted: "Black ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... of actual resveratrol plus 95% OPCs ... and three ... manufacturer,Renaissance Health Publishing, LLC, is disappointed and confused as to ... of Revatrol, and calls on the for-profit laboratory,to remove the ...
... often be the smarter choice, study suggests , MONDAY, Nov. ... symptoms of throat infection, surgery to remove the tonsils is ... watching and waiting to see if symptoms resolve, a Dutch ... University Medical Center Utrecht compared 151 children, ages 2 to ...
... McCandliss, a psychologist at the Sackler Institute for Developmental ... Weill Cornell Medical College, has received a commendation by ... of a Presidential Early Career Award for Scientists and ... by the U.S. government for outstanding scientists and engineers ...
... new article appearing in American Journal of Transplantation describes ... of organ rejection in kidney transplants. The technique, which ... examining DNA sequences, defines how major causes of organ ... behavior. The study is the first to show how ...
... Booker, II, CPA, Presented with Charles Kopke,Medal ... Nov. 19 The American,Diabetes Association (ADA), ... fight against diabetes, announced today that G. ... Arkansas, received the,Association,s prestigious Charles Kopke Medal ...
... an,important step toward protecting patient access to essential ... Fracture Prevention and,Osteoporosis Testing Act of 2007," sponsored ... a reversal of drastic Medicare cuts,to DXA (dual ... the gold standard for measuring bone mass to ...
Cached Medicine News:Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 2Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 3Health News:Tonsillectomy Not Always Cost-Effective for Kids' Throat Woes 2Health News:White House awards Weill Cornell's Bruce McCandliss highest honor for early career scientists 2Health News:Breakthrough in organ rejection diagnosis examines gene behavior 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 3Health News:Congress Moves to Protect Bone Health 2
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... The Blue Line UNO Splint fits small, medium, ... cushioned two-part design includes both dorsal and volar ... extension. Recommended for those experiencing symptoms of Carpal ... for busy clinics - stock one splint to ...
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
Medicine Products: